CAR T Cell Therapy May Change Cancer Patients’ Own Weak T Cells into “Bionic Killing Machines” Aurora Biopharma is a Cambridge, MA-based, clinical-stage company that is developing state-of-the-art cancer immunotherapy, utilizing a form of adoptive cell transfer called Chimeric Antigen Receptor (CAR) T Cell Therapy. The therapy genetically edits patients’ T cells to express a CAR specific to the type of cancer present, which enables targeted killing of cancer cells. The U.S. Food & Drug Administration has awarded Aurora Biopharma’s CAR T Cell Therapy with its Breakthrough Therapy Designation for the therapy’s treatment of pediatric and adult acute lymphoblastic leukemia…